Prianil CR

Lithium

Method of action: Antipsychotic, Psychoanaleptics, Psycholeptics, Sedative

Treatment option: Bipolar Affective Disorder, Bipolar Disorder, Mania

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prianil CR

Quick Facts

Property	Description
Active ingredient	Lithium Carbonate (Lithium Salts)
Form	Controlled-Release Tablet (CR)
Pharmacological class	Mood Stabilizer, Psychotropic Medication
General purpose	Supports long-term emotional balance
Origin	Synthetic Inorganic Compound

What Type of Medicine is Prianil CR? (Classification and Identity)

Prianil CR is a prescription-only medicine whose active component is Lithium Carbonate, formally classified as a core Mood Stabilizer and an Antimanic Agent. It belongs to the foundational category of Psychotropic Medications utilized in long-term psychiatric support, and its efficacy is clinically recognized for its role in stabilizing severe shifts in mood. The active substance is an inorganic ion, a salt of the alkali-metal element lithium, derived from the Lithium Salts used in the formulation. Its classification as a core stabilizing agent is an established role within psychiatric guidelines.

Prianil CR Composition and Extended-Release Form (Composition and Form)

Prianil CR is an Oral Dosage Form containing Lithium Carbonate as the sole active ingredient, confirming it as a single-ingredient product. The key identifier is the suffix CR, which stands for Controlled-Release, signifying that this is a specialized Extended-Release Tablet. This sustained-release formulation is engineered with a polymer matrix, ensuring the Lithium Salts are released slowly and consistently over an extended duration. This design is critical for maintaining stable therapeutic levels, which is essential for minimizing concentration peaks and achieving consistent support.

General Purpose of Prianil CR (Prophylactic Role)

The general purpose of Prianil CR is to support the continuous maintenance of emotional and psychological balance by exerting a stabilizing effect on the Central Nervous System. As a Neuroactive Drug, it modulates certain critical chemical signaling pathways within the brain, helping to regulate the neuronal activity often associated with severe mood shifts. The medication assists the brain in maintaining a more consistent and regulated state, providing prophylactic support to patients aiming for long-term stability in their emotional lives. A typical application is its use as a continuous maintenance therapy for adults.

Regulatory References

Lithium: MedlinePlus Drug Information

What side effects are possible with Prianil CR?

Adverse Reaction Scope

The official safety profile for Prianil CR (Lithium Carbonate) classifies adverse reactions based on their documented frequency and the physiological system affected.

Category	Description / Identified Entities
Frequency classification	Very Common: Fine tremor, polyuria (increased urination), and polydipsia (increased thirst). Common: Nausea, weight gain, fatigue, and mild cognitive changes. Uncommon/Rare: Hypothyroidism, hypercalcemia, and significant cardiac or neurological effects.
System-organ classes involved	Renal/Urinary System (e.g., polyuria, risk of chronic damage); Nervous System (e.g., tremor, seizures); Endocrine/Metabolic (e.g., hypothyroidism, weight gain); and Cardiac/Vascular System (e.g., ECG changes).
Serious adverse reactions	The most critical documented safety risk is Acute Lithium Toxicity, which is closely related to serum concentrations. Other serious label-documented risks include Chronic Renal Impairment associated with prolonged use and Encephalopathic Syndrome.
Population-specific safety considerations	Safety statements address risks during Pregnancy, citing an increased risk of fetal cardiac anomalies, and excretion into breast milk, which is generally not recommended. Older adults are noted to have a higher risk of toxicity due to potential age-related decline in renal function.
Exposure-related patterns	Certain non-serious effects, such as gastrointestinal disturbances and tremor, may be more noticeable at the start of treatment. Conversely, the risk of chronic kidney and thyroid dysfunction is documented to be associated with long-term exposure.

Safety-Related Restrictions

The regulatory safety profile defines specific constraints, including that the medicine should generally be avoided in patients with severe Renal or Cardiovascular Disease. Furthermore, conditions that lead to sodium depletion or dehydration significantly increase the risk of acute toxicity.

Overdose and Emergency Response

The official regulatory profile for Prianil CR (Lithium Carbonate) overdose describes a clear progression of clinical signs that mandate specific emergency actions.

Initial signs of toxicity require immediate discontinuation of the medicine and contact with a healthcare professional. These early manifestations include gastrointestinal distress (diarrhea, vomiting) and neurological changes such as fine hand tremor, increased drowsiness, and mild lack of coordination (ataxia). Due to the controlled-release formulation, the onset of symptoms may be delayed following ingestion.

More severe manifestations necessitate seeking immediate emergency medical assistance. Documented life-threatening outcomes include central nervous system toxicity (seizures, coma, severe confusion) and cardiovascular effects like cardiac dysrhythmias and severe hypotension. Official documentation specifies that no specific antidote for lithium poisoning is known.

Clinical management requires continuous hospital observation for a minimum of 24 hours, focusing on supportive treatment, close monitoring of serum lithium concentrations, and maintenance of fluid and electrolyte balance. Hemodialysis is the treatment of choice for severe toxicity. Geriatric patients and individuals with pre-existing renal or cardiovascular disease are noted to be at an increased risk of toxicity.

Therapeutic Uses of Prianil CR

What Prianil CR Treats: Main Uses and Benefits

Prianil CR (Lithium Carbonate) is generally used as a stabilizing treatment, primarily applied across domains where additional symptomatic support is needed for conditions characterized by severe emotional and behavioral instability. It is considered relevant for easing the acute manifestations and supporting the long-term course of this recurrent illness.

The medication is applied when appropriate for conditions characterized by periods of heightened symptoms, including Bipolar Disorder (both manic and depressive phases), addressing clusters of symptoms related to acute manic symptoms (like hyperactivity and racing thoughts), and is used for managing high-risk behavioral manifestations (such as recurrent aggression and impulsivity).

In these clinical scenarios, Prianil CR is applied during phases of increased distress or discomfort, offering symptomatic relief that helps patients cope more steadily. It is commonly used to help with its supportive role in chronic care, which contributes to maintaining a sense of stability during symptomatic periods.

Quick Fact: Support for Symptom Fluctuations

Therapeutic Focus	Primary Benefit
Maintenance Therapy	Plays a role in managing recurrent episodes, assisting with maintaining functional stability.
Acute Symptoms	Helps address intense, disruptive symptom clusters during sudden escalation.
Behavioral Support	May assist with the management of high-risk manifestations and impulse control issues.

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

The eligibility profile for Prianil CR (Lithium Carbonate CR) is strictly defined by official regulatory criteria that outline who can and cannot use the medication based on the patient's existing health status and age. The rules prioritize managing the high risk of lithium toxicity and systemic effects.

Classification	Eligibility Rules (Official Status)
Absolute Contraindications	Must not use Prianil CR. This applies to individuals with severe renal disease or severe renal impairment, Brugada Syndrome, significant cardiovascular disease, and those experiencing severe dehydration or sodium depletion [FDA Drug Labeling].
Age-Group Eligibility	Use is established for Adult Patients and Pediatric Patients aged 7 years. Safety and effectiveness are not established for children under the age of 7 years [FDA Drug Labeling]. Older Adults require use with caution due to increased susceptibility to toxicity.
Conditional Use & Restriction	Use requires caution and close monitoring in patients with mild or moderate renal insufficiency or pre-existing thyroid disorders. Use is also restricted in patients taking diuretics [Medsafe].
Reproductive Status	Prianil CR is not recommended during pregnancy due to the potential for fetal harm, and nursing should not be undertaken as the medication is excreted in human milk [FDA Drug Labeling].

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Prianil CR (Lithium Carbonate) is primarily defined by agents that affect its renal clearance (a pharmacokinetic interaction) or cause additive Central Nervous System (CNS) effects (a pharmacodynamic interaction). Lithium itself is not metabolized by CYP enzymes.

Documented Pharmacokinetic Interactions

Many medicines can substantially increase serum lithium concentrations by reducing its renal clearance. This includes drug classes such as Diuretics (especially Thiazides), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), and Renin-Angiotensin System Antagonists (ACE Inhibitors and ARBs). Conversely, substances such as Theophylline and Acetazolamide are documented to lower serum lithium concentrations by increasing urinary excretion.

Pharmacodynamic and Substance Interactions

Co-administration with Serotonergic Agents (including SSRIs, Triptans, and St. John’s Wort) increases the risk of Serotonin Syndrome. Combining Lithium with certain Neuroleptics has been formally associated with the risk of an Encephalopathic Syndrome. Furthermore, sodium depletion, resulting from a low-salt diet or dehydration, is documented to reduce renal clearance, functionally increasing the drug's exposure. The severity of these pharmacokinetic interaction risks is heightened in patients with impaired renal function.

Mechanism of Action

How Prianil CR Works: Mechanism of Action

Prianil CR (Lithium Carbonate) works by exerting complex, deep-acting influence on specific intracellular signaling pathways, contributing to the regulation of Central Nervous System (CNS) function.

Attenuation of Hyper-Excitatory Intracellular Signaling

The drug functions as an inhibitor of the key enzyme Inositol Monophosphatase (IMPase), which controls the Phosphoinositol (PI) signaling cycle. This mechanism functionally depletes the inositol pool necessary for generating second messengers, thereby dampening the amplification of signals from excitatory neurotransmitters. This molecular action reduces the overall intensity of stimulated cellular communication and modulates the sustained excitability of neuronal cells, contributing to a lower, regulated frequency of neuronal discharge.

Modulation of Neuroplasticity and Cellular Survival Pathways

Prianil CR engages mechanisms that modulate the structural integrity of nerve cells by inhibiting Glycogen Synthase Kinase-3 (GSK-3 beta). This inhibition results in the upregulation of cell survival factors and protective proteins. This molecular sequence aids in the regulation of neurogenesis and synaptic remodeling within CNS networks, influencing the long-term structural stability of neuronal cells.

Dosage and Administration Information

How Prianil CR is Used

Prianil CR is a Controlled-Release (CR) tablet, and its usage is guided by specific instructions to ensure proper administration and dose stability.

Administration Rules and Procedural Steps

The CR tablet must be swallowed whole and must not be chewed, crushed, or broken. This is a mandatory instruction to preserve the specialized sustained-release profile of the medication. The medicine is administered orally and should be consumed with food to minimize potential gastrointestinal discomfort. If a dose is missed, a double dose must not be taken to compensate.

Official Dosing and Monitoring

Dosage is highly individualized and strictly adjusted based on mandatory, periodic measurements of serum lithium concentration (blood levels). For acute stabilization, the typical adult initial regimen often involves a total daily dose of up to 1800 mg administered in divided doses. For long-term maintenance, the usual total daily dose range is 900 mg to 1200 mg. Blood samples for concentration monitoring must be drawn 8 to 12 hours after the previous dose to measure trough levels.

Contextual Requirements and Adjustments

A key administration context involves maintaining adequate fluid and normal salt intake throughout the course of use. Furthermore, older adults often require a reduced dosage and should initiate treatment at the lowest end of the established dosing range, reflecting the need for caution in this population.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Prianil CR

Evidence for Use in Long-Term Mood Stabilization (Maintenance Treatment)

Research in this area was evaluated in a number of controlled settings. Researchers primarily utilized Randomized Controlled Trials (RCTs) and Systematic Reviews to explore how symptoms change over time in conditions characterized by fluctuating or episodic manifestations. These studies included adults and sometimes pediatric populations with Bipolar I Disorder.

The primary outcomes examined included the frequency of a new manic, depressive, or mixed episode recurrence, and the overall time that elapsed before such an event was tracked in the study groups. Trials extending over several months to years also monitored outcomes reflecting daily functioning or activity level. Aggregated data in systematic reviews characterized the research as being of a High evidence level for this clinical situation.

Evidence for Use in Acute Mood Episodes

The available research for acute mood episodes was studied for short-term symptom changes. These studies were structured as short-term Randomized Controlled Trials (RCTs), where the compound was evaluated against a comparison substance or a placebo. The research included adult patients who were experiencing phases of heightened symptom activity, such as acute mania or mixed states.

The trials examined outcomes capturing phases of heightened symptom activity using standardized psychiatric scales. Studies described the data collected on changes in standardized symptom scores during the initial weeks of treatment. The evidence base for this application is generally described by scientific bodies as a High research level.

Evidence for Use in Managing High-Risk Behaviors

Research exploring outcomes related to self-harm was evaluated in specific analytical settings, including Meta-Analyses and Pooled Analyses of data collected as secondary endpoints in other long-term trials. Researchers also monitored outcomes in groups using Retrospective Cohort Studies over several years. This evidence focused on outcomes related to specific, recorded events like completed suicide and non-fatal suicidal attempts.

Analysis of the aggregated data showed patterns related to the incidence of self-harm behaviors across long-term cohorts. Research examined patterns in the tracking of suicide-related outcomes. The evidence is relevant to understanding symptom patterns in conditions involving periods of heightened symptoms.

Long-Term Studies and Follow-Up

The research exploring long-term use in conditions characterized by fluctuating or episodic manifestations is essential for understanding its use over time. These studies, which have been observed in settings evaluating daily-life functioning, often span many months or even several years. This section provides context but not individual predictions regarding the sustainability of the observed changes.

What is Still Uncertain About the Research for Prianil CR

This research provides insight into short-term changes and long-term patterns, but several areas still require further study. Long-term effects are not fully established beyond the observation windows of the currently published trials, meaning there is limited information for long-term outcomes that span many decades.

Comparative evidence is lacking for many newer therapeutic options. Furthermore, findings were mixed across various studies concerning specific demographic subgroups, meaning the research does not determine whether an individual will respond similarly to the group pattern.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Prianil CR (FAQ)

Q: How quickly can I expect Prianil CR to start working?

The official documentation describes the time frame for realizing the full therapeutic effect as typically one to three weeks or longer. This time frame applies from the start of treatment.

Q: Can Prianil CR cause unusual mood changes or emotional effects?

Official documentation lists mood changes and confusion among the documented possible effects. The official safety profile notes that these are potential effects of the medication.

Q: Is it common for Prianil CR to cause dizziness or lightheadedness?

Official safety documents list dizziness as a documented side effect, categorized under a specific frequency classification. Dizziness is also listed as a symptom that may be associated with potential lithium toxicity.

Q: Does Prianil CR interact with common supplements like multivitamins?

Official labeling advises patients to discuss all over-the-counter products with their healthcare provider, including vitamins and herbal supplements, before beginning use. This is necessary to review the full interaction profile for any substances that could affect Prianil CR's action or safety.

Q: Can Prianil CR affect my ability to drive or operate machinery?

Official warnings state that the medication may impair mental and physical abilities necessary for activities such as operating vehicles or heavy machinery. This warning is provided until a patient knows how the drug affects them.

Q: What does 'CR' stand for in Prianil CR?

The suffix 'CR' stands for Controlled-Release. This signifies a specialized extended-release formulation designed to release the active ingredient slowly and consistently into the body over an extended period.

Q: What kind of research evidence supports the use of Prianil CR?

Studies, including Randomized Controlled Trials and Systematic Reviews, characterize the evidence for its use in long-term mood stabilization and acute mood episodes as being of a High evidence level. This means the research supporting these applications is considered robust by scientific bodies.

Q: Do children or teenagers ever take Prianil CR?

Official eligibility rules establish use for pediatric patients aged 7 years and older. Safety and effectiveness are not established for children under the age of 7.

Q: What happens if I miss a dose of Prianil CR?

Official patient information states that if a dose is missed, the next dose should be taken at the regularly scheduled time, and no extra doses should be taken to compensate for the missed dose.

Q: How long does Prianil CR typically stay in your system?

Pharmacokinetics studies often describe the elimination half-life of lithium, the active ingredient in Prianil CR, as approximately 24 hours. This time frame represents how long it takes for half of the drug to be eliminated from the body.

Q: Does Prianil CR interact with alcohol?

Official safety information documents a warning against the use of alcohol due to the potential to increase sedating side effects and the risk of dehydration and toxicity.

Q: Can Prianil CR affect fertility?

Studies conducted in animals have examined potential adverse effects on aspects of reproductive health, including embryo viability and the metabolism of certain reproductive cells.

Q: Can Prianil CR affect my blood pressure?

Changes in high or low blood pressure are listed in official documents as potential symptoms associated with a serious adverse event known as Serotonin Syndrome. This event is associated with co-administration of certain medications.

Q: Can Prianil CR cause weight gain or loss?

Official documentation lists weight gain as a common documented side effect of Prianil CR. Conversely, weight loss is not listed in the official frequency classification for this medication.

Q: Why is Prianil CR usually taken once a day?

The Controlled-Release (CR) formulation is engineered to release the active ingredient slowly, which helps to reduce the variability in blood levels and maintain a stable therapeutic concentration over an extended time.

Q: Can Prianil CR affect my blood sugar levels?

The official adverse reactions list includes documented reports of Glycosuria (which is sugar in the urine). This finding relates to the body's glucose balance and is part of the genitourinary section of the safety profile.

Q: What common over-the-counter medications might interact with Prianil CR?

The official drug interaction profile documents that common over-the-counter medications can interact with Prianil CR, with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) being specified as having a significant interaction.

How should Prianil CR be stored and disposed of?

How to Store and Dispose of Prianil CR?

All storage and disposal of Prianil CR (Lithium Carbonate Extended-Release Tablets) must strictly adhere to the conditions mandated in government-approved labeling.

Storage Conditions

Prianil CR must be stored at controlled room temperature, specifically between 15 C and 30 C (59 F and 86 F). The product must be protected from moisture and must not be frozen.

Packaging and Safety

Storage requires using a tight, child-resistant container that must be kept tightly closed to maintain product integrity. The medication must be stored out of the reach of children.

Disposal Instructions

Unused or expired Prianil CR must be disposed of according to local regulations. Patients should consult a healthcare professional or pharmacist for guidance on proper disposal, as local guidelines often recommend specific pharmaceutical waste protocols.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Egypt

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z